ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)
Sweden
· Delayed Price · Currency is SEK 5.87
-0.07 (-1.18%)
At close: Mar 6, 2026
STO:EXPRS2 Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Operating Revenue | 3.82 | 3.01 | 7.05 | 5.09 | 12.23 | 5.26 | Upgrade
|
| Other Revenue | 7.03 | 4.81 | 1.75 | 1.06 | 1.5 | 10 | Upgrade
|
| Revenue | 10.85 | 7.83 | 8.8 | 6.15 | 13.73 | 15.26 | Upgrade
|
| Revenue Growth (YoY) | 36.83% | -11.07% | 43.07% | -55.21% | -10.04% | 10.37% | Upgrade
|
| Cost of Revenue | 4.81 | 5.68 | 3.65 | 5.08 | 7.51 | 6.1 | Upgrade
|
| Gross Profit | 6.04 | 2.14 | 5.15 | 1.07 | 6.22 | 9.16 | Upgrade
|
| Selling, General & Admin | 44.24 | 41.54 | 58.1 | 56.14 | 35.89 | 37.22 | Upgrade
|
| Research & Development | 14.07 | 26.66 | 51.42 | 71.32 | 9.82 | 0.22 | Upgrade
|
| Operating Expenses | 59.83 | 69.84 | 111.12 | 128.68 | 47.51 | 40.36 | Upgrade
|
| Operating Income | -53.79 | -67.7 | -105.97 | -127.61 | -41.3 | -31.2 | Upgrade
|
| Interest Expense | -0.46 | -0.73 | -0.5 | -0.87 | - | -3.53 | Upgrade
|
| Interest & Investment Income | 0.67 | 1.71 | 1.91 | 1.9 | - | - | Upgrade
|
| Earnings From Equity Investments | 0.04 | 22.15 | 4.59 | - | 0.67 | -0.19 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | 0.21 | - | Upgrade
|
| EBT Excluding Unusual Items | -53.53 | -44.56 | -99.97 | -126.58 | -40.42 | -34.92 | Upgrade
|
| Other Unusual Items | - | - | - | - | -7.1 | - | Upgrade
|
| Pretax Income | -53.53 | -44.56 | -99.97 | -126.58 | -47.52 | -34.92 | Upgrade
|
| Income Tax Expense | -8.36 | -8.53 | -8.57 | -7.98 | -3.59 | -3.21 | Upgrade
|
| Net Income | -45.17 | -36.04 | -91.4 | -118.61 | -43.93 | -31.71 | Upgrade
|
| Net Income to Common | -45.17 | -36.04 | -91.4 | -118.61 | -43.93 | -31.71 | Upgrade
|
| Shares Outstanding (Basic) | 3 | 2 | 1 | 1 | 1 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 2 | 1 | 1 | 1 | 0 | Upgrade
|
| Shares Change (YoY) | 75.26% | 46.56% | 31.49% | 20.02% | 68.61% | 31.36% | Upgrade
|
| EPS (Basic) | -17.71 | -21.31 | -79.22 | -135.18 | -60.09 | -73.14 | Upgrade
|
| EPS (Diluted) | -17.71 | -21.31 | -79.22 | -135.18 | -60.09 | -73.14 | Upgrade
|
| Free Cash Flow | -47.08 | -34.8 | -102.9 | -100 | -46.36 | -19.06 | Upgrade
|
| Free Cash Flow Per Share | -18.46 | -20.58 | -89.19 | -113.97 | -63.42 | -43.96 | Upgrade
|
| Gross Margin | 55.64% | 27.40% | 58.55% | 17.38% | 45.28% | 60.02% | Upgrade
|
| Operating Margin | -495.67% | -865.11% | -1204.28% | -2074.89% | -300.78% | -204.39% | Upgrade
|
| Profit Margin | -416.26% | -460.55% | -1038.77% | -1928.54% | -319.92% | -207.78% | Upgrade
|
| Free Cash Flow Margin | -433.87% | -444.70% | -1169.47% | -1625.97% | -337.66% | -124.88% | Upgrade
|
| EBITDA | -52.27 | -66.05 | -104.37 | -126.35 | -39.8 | -28.28 | Upgrade
|
| EBITDA Margin | - | - | - | - | -289.87% | -185.29% | Upgrade
|
| D&A For EBITDA | 1.52 | 1.64 | 1.6 | 1.25 | 1.5 | 2.92 | Upgrade
|
| EBIT | -53.79 | -67.7 | -105.97 | -127.61 | -41.3 | -31.2 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -204.39% | Upgrade
|
| Revenue as Reported | 10.85 | 7.83 | 8.8 | 6.15 | 13.73 | 15.26 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.